Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | FAAH | O00519 | 1/20 | 0.56 |
| ▸ | SIRT2 | Q8IXJ6 | 10/20 | 0.53 |
| ▸ | SIRT1 | Q96EB6 | 5/20 | 0.53 |
| ▸ | SIRT3 | Q9NTG7 | 4/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11639997 | 0.99 | TGM2 (0.57) | TGM2HTTHPGDFAAHSIRT2 | |
| SCHEMBL30576727 | 0.99 | TGM2 (0.57) | TGM2HTTHPGDFAAHSIRT2 | |
| SCHEMBL7751024 | 0.93 | FAAH (0.66) | TGM2HTTHPGDFAAHSIRT2 | |
| SCHEMBL11973884 | 0.89 | HTT (0.68) | TGM2HTTHPGDFAAHSIRT2 | |
| SCHEMBL10599151 | 0.89 | HTT (0.68) | TGM2HTTHPGDFAAHSIRT2 | |
| SCHEMBL28969063 | 0.89 | HTT (0.68) | TGM2HTTHPGDFAAHSIRT2 | |
| SCHEMBL3364812 | 0.89 | HTT (0.68) | TGM2HTTHPGDFAAHSIRT2 | |
| SCHEMBL16692630 | 0.89 | HTT (0.68) | TGM2HTTHPGDFAAHSIRT2 | |
| SCHEMBL10659971 | 0.89 | HTT (0.68) | TGM2HTTHPGDFAAHSIRT2 | |
| SCHEMBL14542740 | 0.88 | LMNA (0.57) | HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032694-A1 | STENTS WITH A RADIOACTIVE SURFACE COATING, PROCESSES FOR THEIR PRODUCTION AND THEIR USE FOR RESTENOSIS PROPHYLAXIS | DINKELBORG LUDGER | 2007-02-08 | — | — | US | disclosed |
| US-6709693-B1 | WITHOUT USE OF CYCLOTRON | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-03-23 | — | — | US | disclosed |
| US-6436365-B2 | ADMINISTRATION VIA CATHETER OF RADIOACTIVE METAL COMPLEX TO SITE OF LEGION; TREATMENT OF ATHERSCLEROSIS; REDUCES UNDESIRED RADIOACTIVE EXPOSURE OF HEALTHY TISSUE | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-08-20 | — | — | US | disclosed |
| US-20020004031-A1 | PROCESS FOR THERAPEUTIC TREATMENT OF PROLIFERATIVE DISEASES | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-01-10 | — | — | US | disclosed |
| EP-1011737-A2 | METHOD FOR TREATING PROLIFERATIVE DISEASES BY THERAPY | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-06-28 | — | — | EP | disclosed |
| CN-1254295-A | Surface-coated spring, method for the production thereof and use thereof for preventing restenosis | SCHERING AG (DE) | 2000-05-24 | — | — | CN | disclosed |
| EP-0979108-A2 | STENTS WITH A RADIOACTIVE SURFACE COATING, PROCESSES FOR PRODUCING THE SAME AND THEIR USE FOR RESTENOSIS PREVENTION | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-02-16 | — | — | EP | disclosed |
| WO-1999013920-A2 | METHOD FOR TREATING PROLIFERATIVE DISEASES BY THERAPY | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-03-25 | — | — | WO | disclosed |
| WO-1998048851-A2 | STENTS WITH A RADIOACTIVE SURFACE COATING | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020004031-A1 | PROCESS FOR THERAPEUTIC TREATMENT OF PROLIFERATIVE DISEASES | MKI67, FGF2, FGFR1 | TGM2 2102/4885HTT 545/4885HPGD 1252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.